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Title:
Multiple Sclerosis Impact Scale and brain volume are independent predictors of cognitive impairment in
secondary progressive multiple sclerosis.
Background and Aims:
Cognitive deficits in multiple sclerosis (MS) affect up to 70% of patients with progressive MS. We investigate
the associations between the disease specific Multiple Sclerosis Impact Scale psychological subscale (MSIS-
29v2-PSYCH), magnetic resonance image (MRI) normalised brain volume and cognitive impairment in people
with secondary progressive MS(SPMS).
Methods:
A group of SPMS patients were recruited at baseline from a randomised phase 2 clinical trial(MS-SMART).
Patients were assessed using a cognitive test battery(Table 1) to define cognitive status based on conservative
criteria (standard deviation of z-score of -1.96 on 2 tests), and completed the MSIS-29v2 questionnaire.
Normalised brain volume(NBV) was measured using the geodesic information flow and SIENAX algorithms. We
analysed associations of cognitive impairment with MSIS-29-v2-PSYCH subscale and brain volume using binary
logistic regression(Figure 3).
Results:
60 subjects were analysed with baseline characteristics shown in Table 2. We find NBV and MSIS-29v2-PSYCH
to be independent predictors of cognitive impairment after adjusting for age, gender and years of education (Figure
3). There is a significant negative association between NBV and cognitive impairment (OR: 0.45; 95% CI: 0.21-
0.84; p=0.0191) and a significant positive association between MSIS-29-PSYCH and cognitive impairment (OR:
1.89; 95% CI: 1.03-3.72; p=0.0491).
Conclusion:
Baseline MSIS-29v2-PSYCH has the potential to be a predictor of cognitive impairment in a SPMS patients.
Longitudinal data will confirm the role of this self-reported outcome measure as a marker of MS future cognitive
status.
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